Janssen Sciences Ireland Uc

๐Ÿ‡ฎ๐Ÿ‡ชIreland
Ownership
Private
Employees
-
Market Cap
-
Website

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-12-23
Last Posted Date
2020-09-30
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
16
Registration Number
NCT04208386
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-12-23
Last Posted Date
2021-04-20
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
16
Registration Number
NCT04208399
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

APEX GmbH, Munchen, Germany

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

First Posted Date
2019-10-17
Last Posted Date
2024-07-31
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
130
Registration Number
NCT04129554
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

Universitatsklinikum Essen, Essen, Germany

๐Ÿ‡ซ๐Ÿ‡ท

Hopital de La Croix Rousse, Lyon, France

๐Ÿ‡ฉ๐Ÿ‡ช

ICH Study Center GmbH & Co. KG, Hamburg, Germany

and more 38 locations

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

First Posted Date
2019-08-14
Last Posted Date
2023-04-14
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
3
Registration Number
NCT04056611
Locations
๐Ÿ‡ง๐Ÿ‡ช

Jules Bordet Institute, Brussels, Belgium

๐Ÿ‡ง๐Ÿ‡ช

CHU de Liรจge, Liege, Belgium

๐Ÿ‡ฆ๐Ÿ‡บ

Royal Melbourne Hospital, Melbourne, Australia

and more 66 locations

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-07-01
Last Posted Date
2019-09-26
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
25
Registration Number
NCT04002752
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

PAREXEL International, London, United Kingdom

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

First Posted Date
2019-06-11
Last Posted Date
2024-07-10
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
471
Registration Number
NCT03982186
Locations
๐Ÿ‡ท๐Ÿ‡บ

Medical Company Hepatolog Ltd, Samara, Russian Federation

๐Ÿ‡น๐Ÿ‡ท

Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

๐Ÿ‡ต๐Ÿ‡ฑ

ID Clinic, Myslowice, Poland

and more 105 locations

A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-05-10
Last Posted Date
2019-11-27
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
16
Registration Number
NCT03945539
Locations
๐Ÿ‡ง๐Ÿ‡ช

Clinical Pharmacology Unit, Merksem, Belgium

A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

First Posted Date
2018-03-13
Last Posted Date
2021-04-14
Lead Sponsor
Janssen Sciences Ireland UC
Target Recruit Count
30
Registration Number
NCT03463369
Locations
๐Ÿ‡ง๐Ÿ‡ช

Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels, Belgium

๐Ÿ‡ฉ๐Ÿ‡ช

UK Leipzig, Leipzig, Germany

๐Ÿ‡ฌ๐Ÿ‡ง

Bart's Health - Blizard Inst. London, London, United Kingdom

and more 11 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath